Related Experiment Video
Updated: Apr 16, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
Beta-amyloid imaging with florbetaben.
Osama Sabri1, John Seibyl2, Christopher Rowe3
1Leipzig University, Leipzig, Germany.
Florbetaben, a novel PET tracer, effectively visualizes amyloid plaques in Alzheimer's disease (AD) brains. It is now approved for clinical use, aiding in AD diagnosis and prognosis.
Area of Science:
- Neurology
- Radiochemistry
- Nuclear Medicine
Background:
- Alzheimer's disease (AD) is characterized by β-amyloid plaque accumulation.
- Accurate diagnosis and monitoring of AD are crucial for effective patient management.
- Novel imaging biomarkers are needed to improve diagnostic accuracy and therapeutic strategies.
Conclusions:
- Florbetaben is a valuable β-amyloid-targeting PET tracer for clinical use.
- It serves as a biomarker supporting the diagnosis of Alzheimer's disease.
- Approved by regulatory agencies, florbetaben offers significant potential for routine clinical application in AD management.
More Related Videos
08:25Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease
Published on: April 19, 2021
09:03Radiotracer Administration for High Temporal Resolution Positron Emission Tomography of the Human Brain: Application to FDG-fPET
Published on: October 22, 2019
Related Concept Videos
Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET